Seattle Genetics Inc's brentuximab vedotin [Adcetris] could be priced at more than $US100 000

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.636, 2011-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Brentuximab Vedotin

Drugs in R&D, Vol. 11, Iss. 1, 2011-03 ,pp. : 85-95

Adis International

Access to resources Recommend Favorite

Brentuximab vedotin: Progressive multifocal leukoencephalopathy: case report

Reactions Weekly, Vol. 1, Iss. 1431, 2012-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells

By Ansell Stephen M

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 1, 2011-01 ,pp. : 99-105

Informa Healthcare

Access to resources Recommend Favorite

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 174-181

John Wiley & Sons Inc

Access to resources Recommend Favorite

Aspirin more cost effective than clopidogrel in the US

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 367, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite